Amneal Pharmaceuticals, Inc. AMRX Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s pre-tax income?
- Amneal Pharmaceuticals, Inc. (AMRX) reported pre-tax income of $80.18M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s pre-tax income changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s pre-tax income increased by 113.9% year-over-year, from $37.49M to $80.18M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s pre-tax income?
- Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s pre-tax income has grown at a -17.5% compound annual growth rate (CAGR), from -$248.13M to $139.21M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.